RecruitingNCT06669585

Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 3

Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 3 (COBRA)


Sponsor

L. Cinnamon Bidwell

Enrollment

64 participants

Start Date

Oct 9, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This study investigates the impact of ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on recognition memory in healthy, regular cannabis users. Participants complete the same recognition memory task after self-administering one of two different strains of cannabis flower one day and while not intoxicated another day. Event-related potentials (ERPs) are measured via electroencephalogram (EEG) during the recognition memory task. Blood is collected to quantify THC and CBD exposure. Participants also complete self-report measures of medical history, sleep quality, subjective cognitive function, physical activity, psychological functioning, substance use, and acute drug effects.


Eligibility

Min Age: 21 YearsMax Age: 40 Years

Inclusion Criteria14

  • Must be between the ages of 21 and 40 and provide informed consent;
  • Must be right-handed (Laterality Quotient > 60 on Edinburgh Handedness Inventory - Short Form);
  • Must use cannabis at least 4 days during the month;
  • Must be a cannabis user for at least a year;
  • Must self-report not using other illicit recreational drugs (e.g., cocaine, benzodiazepines (non-prescription), opiates (non-prescription), MDMA, sedatives, or methamphetamine) in the past 30 days, during the Pre-Screening;
  • Must not test positive on a urine toxicology test for drugs of abuse at the Baseline appointment;
  • Must not be using psychotropic medications, however anti-depressant, non-benzodiazepine anti-anxiety, and ADHD medications are ok. ADHD medication users must be willing to abstain from ADHD medication use on appointment days;
  • Must not be a regular nicotine user (≤4 days per week; cigarette, E-cigs, or smokeless);
  • Must not have used caffeine or nicotine (cigarette, E-cigs, or smokeless) for 4 hours before each appointment;
  • Must have a breath alcohol level of 0 at Baseline appointment (to sign consent form);
  • Must not be actively seeking or in treatment for any substance use disorder;
  • Female subjects must not be or trying to become pregnant (as indicated by a pregnancy test administered at Baseline appointment);
  • Must not be in treatment for psychotic disorder or bipolar disorder; or have a history with these disorders;
  • Must not have any physical characteristics (e.g., thick hair, head size exceeding the limit of the net, dyed hair) or experience any technical difficulties during testing that result in a poor-quality EEG recording.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCannabis (smoked flower)

Self-Directed Use (ad-libitum)


Locations(1)

Center for Innovation and Creativity (CINC)

Boulder, Colorado, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06669585


Related Trials